Functional Liver Recovery After Bariatric Surgery—a Prospective Cohort Study with the LiMAx Test

Obesity Surgery

Volumn 25, Issue 11, 2015, Pages 2047-2053

  Alizai, Patrick H ^a   Wendl, Janica ^a   Roeth, Anjali A ^a   Klink, Christian D ^a   Luedde, Tom ^a   Steinhoff, Inga ^a   Neumann, Ulf P ^a   Schmeding, Maximilian ^a   Ulmer, Florian ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Bariatric surgery; LiMAx; Liver function; Liver regeneration; NAFLD; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOCHROME P450 1A2; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONVALESCENCE; DYSLIPIDEMIA; END TO SIDE ANASTOMOSIS; FEMALE; GASTROJEJUNOSTOMY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; LAPAROSCOPIC SURGERY; LENGTH OF STAY; LIMAX TEST; LIVER BIOPSY; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER REGENERATION; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ROUX Y ANASTOMOSIS; SLEEP DISORDERED BREATHING; SLEEVE GASTRECTOMY; SMOKING; STOMACH BYPASS; STOMACH POUCH; WEIGHT REDUCTION; FOLLOW UP; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE PERIOD; PROCEDURES; REHABILITATION; STATISTICS AND NUMERICAL DATA;

ADULT; BARIATRIC SURGERY; BODY MASS INDEX; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; POSTOPERATIVE PERIOD; RECOVERY OF FUNCTION;

EID: 84942382735     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1664-0     Document Type: Article

References (45)

1. Yatsuya H, Li Y, Hilawe EH, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J. 2014;78:2807–18.
2. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9.
3. Runkel N, Colombo-Benkmann M, Huttl TP, et al. Evidence-based German guidelines for surgery for obesity. Int J Color Dis. 2011;26:397–404.
4. Haslam DW, James WPT. Obesity. Lancet. 2005;366:1197–209.
5. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014;370:2002–13.
6. Angulo P. Medical progress—nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
7. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760–71.
8. Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev. 2011;27:419–24.
9. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.
10. Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes. 2007;31:569–77.
11. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.
12. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis. 2012;32:80–91.
13. Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621–32.
14. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.
15. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013;2013:839275.
16. Strassburg CP, Manns MP. Approaches to liver biopsy techniques—revisited. Semin Liver Dis. 2006;26:318–27.
17. Assy N, Minuk GY. Liver regeneration: methods for monitoring and their applications. J Hepatol. 1997;26:945–52.
18. Lock JF, Malinowski M, Seehofer D, et al. Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity. Langenbecks Arch Surg. 2012;397:1297–304.
19. Hoekstra LT, de Graaf W, Nibourg GAA, et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg. 2013;257:27–36.
20. Stockmann M, Lock JF, Riecke B, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–25.
21. Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB. 2010;12:139–46.
22. Lock JF, Schwabauer E, Martus P, et al. Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl. 2010;16:172–80.
23. Kaffarnik MF, Lock JF, Vetter H, et al. Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test. Crit Care. 2013;17(5):R259.
24. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
25. Longerich T, Flechtenmacher C, Schirmacher P. Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases. Pathologe. 2008;29:15–26.
26. Barsic N, Lerotic I, Smircic-Duvnjak L, et al. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18:3945–54.
27. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.
28. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010–4.
29. Sjostrom L, Narbro K, Sjostrom D, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.
30. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21:27–41.
31. Tilg H, Diehl AM. Mechanisms of disease: cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467–76.
32. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.
33. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–40.
34. Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol. 2006;101:368–73.
35. Moretto M, Kupski C, da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22:1044–9.
36. Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis. 2008;28:407–26.
37. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135:48–58.
38. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.
39. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.
40. Verma S, Jensen D, Hart J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398–405.
41. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792–8.
42. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–50.
43. Wong VWS, Vergniol J, Wong GLH, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–62.
44. Yoneda M, Yoneda M, Fujita K, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD) (vol 56, pg 1330, 2007). Gut. 2007;56:1800.
45. Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006;18:411–2.